{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T01:51:58Z","timestamp":1792547518409,"version":"4.5.0"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.ejca.2024.114276","type":"journal-article","created":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T07:19:15Z","timestamp":1723187955000},"page":"114276","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Sunitinib for the treatment of patients with advanced pheochromocytomas or paragangliomas: The phase 2 non-randomized SUTNET clinical trial"],"prefix":"10.1016","volume":"209","author":[{"given":"Vincenzo","family":"Nasca","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Prinzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorgelina","family":"Coppa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Prisciandaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Oldani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Ghelardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Conca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iolanda","family":"Capone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adele","family":"Busico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Perrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Tamborini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Sabella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Greco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca Gabriella","family":"Greco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Tafuto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Procopio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Morano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Niger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Maccauro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Milione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"de Braud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Pietrantonio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Pusceddu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2024.114276_bib1","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s12022-017-9484-5","article-title":"Update on adrenal tumours in 2017 World Health Organization (WHO) of endocrine tumours","volume":"28","author":"Lam","year":"2017","journal-title":"Endocr Pathol"},{"key":"10.1016\/j.ejca.2024.114276_bib2","doi-asserted-by":"crossref","first-page":"515","DOI":"10.3389\/fendo.2018.00515","article-title":"Update of pheochromocytoma syndromes: genetics, biochemical evaluation, and imaging","volume":"9","author":"Alrezk","year":"2018","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.ejca.2024.114276_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0022-5347(17)37119-7","article-title":"Extra-adrenal pheochromocytoma","volume":"147","author":"Whalen","year":"1992","journal-title":"J Urol"},{"key":"10.1016\/j.ejca.2024.114276_bib4","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1210\/jc.2014-1498","article-title":"Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline","volume":"99","author":"Lenders","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ejca.2024.114276_bib5","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/ncpendmet0396","article-title":"Pheochromocytoma: recommendations for clinical practice from the First International Symposium","volume":"3","author":"Pacak","year":"2007","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.ejca.2024.114276_bib6","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.jss.2017.04.011","article-title":"Nationwide review of hormonally active adrenal tumors highlights high morbidity in pheochromocytoma","volume":"215","author":"Parikh","year":"2017","journal-title":"J Surg Res"},{"key":"10.1016\/j.ejca.2024.114276_bib7","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.ijcard.2017.07.014","article-title":"Pheochromocytoma as a reversible cause of cardiomyopathy: analysis and review of the literature","volume":"249","author":"Zhang","year":"2017","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.ejca.2024.114276_bib8","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1530\/EJE-19-0159","article-title":"Pheochromocytoma and paraganglioma: clinical feature-based disease probability in relation to catecholamine biochemistry and reason for disease suspicion","volume":"181","author":"Geroula","year":"2019","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ejca.2024.114276_bib9","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1016\/j.ejca.2011.07.016","article-title":"Plasma methoxytyramine: a novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status","volume":"48","author":"Eisenhofer","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2024.114276_bib10","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1245\/s10434-020-08220-3","article-title":"Update on pheochromocytoma and paraganglioma from the sso endocrine\/head and neck disease-site work group. Part 1 of 2: advances in pathogenesis and diagnosis of pheochromocytoma and paraganglioma","volume":"27","author":"Patel","year":"2020","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejca.2024.114276_bib11","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/BF00353738","article-title":"The\u2019 pheochromocytoma: a benign, intra-adrenal, hypertensive, sporadic unilateral tumor. Does it exist","volume":"18","author":"Proye","year":"1994","journal-title":"World J Surg"},{"key":"10.1016\/j.ejca.2024.114276_bib12","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1530\/eje.0.1410619","article-title":"Pheochromocytoma in Italy: a multicentric retrospective study","volume":"141","author":"Mannelli","year":"1999","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ejca.2024.114276_bib13","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1210\/jc.2010-1946","article-title":"Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators","volume":"96","author":"Ayala-Ramirez","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ejca.2024.114276_bib14","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.3390\/cancers11101505","article-title":"Current management of pheochromocytoma\/paraganglioma: a guide for the practicing clinician in the era of precision medicine","volume":"11","author":"N\u00f6lting","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.ejca.2024.114276_bib15","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1210\/jc.2017-02030","article-title":"Phase 1 study of high-specific-activity I-131 MIBG for metastatic and\/or recurrent pheochromocytoma or paraganglioma","volume":"103","author":"Noto","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ejca.2024.114276_bib16","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2967\/jnumed.118.217463","article-title":"Efficacy and safety of high-specific-activity 131I-MIBG therapy in patients with advanced pheochromocytoma or paraganglioma","volume":"60","author":"Pryma","year":"2019","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ejca.2024.114276_bib17","doi-asserted-by":"crossref","first-page":"952","DOI":"10.3390\/jcm8070952","article-title":"A clinical efficacy of PRRT in patients with advanced, nonresectable, paraganglioma-pheochromocytoma, related to SDHx gene mutation","volume":"8","author":"Kolasinska-\u0106wik\u0142a","year":"2019","journal-title":"J Clin Med"},{"key":"10.1016\/j.ejca.2024.114276_bib18","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1002\/jso.24553","article-title":"Peptide Receptor Radionuclide Treatment and (131)I-MIBG in the management of patients with metastatic\/progressive phaeochromocytomas and paragangliomas","volume":"115","author":"Nastos","year":"2017","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.ejca.2024.114276_bib19","doi-asserted-by":"crossref","first-page":"267","DOI":"10.7326\/0003-4819-109-4-267","article-title":"Malignant pheochromocytoma: effective treatment with a combination of cyclophosphamide, vincristine, and dacarbazine","volume":"109","author":"Averbuch","year":"1988","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ejca.2024.114276_bib20","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.1002\/ijc.28913","article-title":"SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma","volume":"135","author":"Hadoux","year":"2014","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ejca.2024.114276_bib21","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/cen.12542","article-title":"Chemotherapy with cyclophosphamide, vincristine and dacarbazine for malignant paraganglioma and pheochromocytoma: systematic review and meta-analysis","volume":"81","author":"Niemeijer","year":"2014","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.ejca.2024.114276_bib22","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1007\/s12094-021-02622-9","article-title":"Multidisciplinary practice guidelines for the diagnosis, genetic counseling and treatment of pheochromocytomas and paragangliomas","volume":"23","author":"Garcia-Carbonero","year":"2021","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.ejca.2024.114276_bib23","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1038\/s41416-019-0474-x","article-title":"A phase 2 trial of sunitinib in patients with progressive paraganglioma or pheochromocytoma: the SNIPP trial","volume":"120","author":"O\u2019Kane","year":"2019","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2024.114276_bib24","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1038\/modpathol.2013.233","article-title":"Tyrosine kinase receptors as molecular targets in pheochromocytomas and paragangliomas","volume":"27","author":"Cassol","year":"2014","journal-title":"Mod Pathol"},{"key":"10.1016\/j.ejca.2024.114276_bib25","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1007\/s12020-017-1359-5","article-title":"Phase II trial of pazopanib in advanced\/progressive malignant pheochromocytoma and paraganglioma","volume":"57","author":"Jasim","year":"2017","journal-title":"Endocrine"},{"key":"10.1016\/j.ejca.2024.114276_bib26","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1177\/03008916221078621","article-title":"Metastatic pheochromocytomas and paragangliomas: where are we?","volume":"108","author":"Prinzi","year":"2022","journal-title":"Tumori"},{"key":"10.1016\/j.ejca.2024.114276_bib27","doi-asserted-by":"crossref","first-page":"808","DOI":"10.3390\/cancers4030808","article-title":"Succinate dehydrogenase B subunit immunohistochemical expression predicts aggressiveness in well differentiated neuroendocrine tumors of the ileum","volume":"4","author":"Milione","year":"2012","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ejca.2024.114276_bib28","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ccell.2017.01.001","article-title":"Comprehensive molecular characterization of pheochromocytoma and paraganglioma","volume":"31","author":"Fishbein","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejca.2024.114276_bib29","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/S0140-6736(23)02554-0","article-title":"Sunitinib for metastatic progressive phaeochromocytomas and paragangliomas: results from FIRSTMAPPP, an academic, multicentre, international, randomised, placebo-controlled, double-blind, phase 2 trial","volume":"403","author":"Baudin","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2024.114276_bib30","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1590\/2359-3997000000217","article-title":"Sunitinib in the therapy of malignant paragangliomas: report on the efficacy in a SDHB mutation carrier and review of the literature","volume":"61","author":"Canu","year":"2016","journal-title":"Arch Endocrinol Metab"},{"key":"10.1016\/j.ejca.2024.114276_bib31","unstructured":"NCCN Clinical Practice Guidelines in Oncology. NCCN Clinical Practice Guidelines in Oncology: Neuroendocrine and Adrenal Tumors Version 1.2023. Neuroendocrine and Adrenal Tumors Version 1.2023 \u2014 August 2, 2023 \u3008https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/neuroendocrine.pdf\u3009."},{"key":"10.1016\/j.ejca.2024.114276_bib32","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.radonc.2012.11.002","article-title":"Regression and local control rates after radiotherapy for jugulotympanic paragangliomas: Systematic review and meta-analysis","volume":"106","author":"van Hulsteijn","year":"2013","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ejca.2024.114276_bib33","article-title":"Catecholamine-secreting carotid body paraganglioma: successful preoperative control of hypertension and clinical symptoms using high-dose long-acting octreotide","volume":"2014","author":"Elshafie","year":"2014","journal-title":"Endocrinol, Diabetes Metab Case Rep"},{"key":"10.1016\/j.ejca.2024.114276_bib34","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1046\/j.1365-2265.2002.01658.x","article-title":"Effects of slow-release octreotide on urinary metanephrine excretion and plasma chromogranin A and catecholamine levels in patients with malignant or recurrent phaeochromocytoma","volume":"57","author":"Lamarre-Cliche","year":"2002","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.ejca.2024.114276_bib35","doi-asserted-by":"crossref","first-page":"909","DOI":"10.3390\/cancers11070909","article-title":"Favorable outcome in patients with pheochromocytoma and paraganglioma treated with 177Lu-DOTATATE","volume":"11","author":"Vyakaranam","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.ejca.2024.114276_bib36","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1210\/jc.2017-00816","article-title":"Efficacy of peptide receptor radionuclide therapy for functional metastatic paraganglioma and pheochromocytoma","volume":"102","author":"Kong","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ejca.2024.114276_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100171","article-title":"Peptide receptor radionuclide therapy in patients with metastatic progressive pheochromocytoma and paraganglioma: long-term toxicity, efficacy and prognostic biomarker data of phase II clinical trials","volume":"6","author":"Severi","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.ejca.2024.114276_bib38","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1200\/JCO.2010.33.7873","article-title":"Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers","volume":"29","author":"Imhof","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2024.114276_bib39","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.3390\/jcm12041494","article-title":"Response to peptide receptor radionuclide therapy in pheocromocytomas and paragangliomas: a systematic review and meta-analysis","volume":"12","author":"Marretta","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.ejca.2024.114276_bib40","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13550-019-0484-y","article-title":"Concomitant 177Lu-DOTATATE and capecitabine therapy in malignant paragangliomas","volume":"9","author":"Yadav","year":"2019","journal-title":"EJNMMI Res"},{"key":"10.1016\/j.ejca.2024.114276_bib41","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1507\/endocrj.EJ14-0211","article-title":"Effects and safety of 131I-metaiodobenzylguanidine (MIBG) radiotherapy in malignant neuroendocrine tumors: results from a multicenter observational registry","volume":"61","author":"Yoshinaga","year":"2014","journal-title":"Endocr J"},{"key":"10.1016\/j.ejca.2024.114276_bib42","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/cen.12341","article-title":"131)I-MIBG therapy for malignant paraganglioma and phaeochromocytoma: systematic review and meta-analysis","volume":"80","author":"van Hulsteijn","year":"2014","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.ejca.2024.114276_bib43","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1002\/cncr.26577","article-title":"Clinical benefits of systemic chemotherapy for patients with metastatic pheochromocytomas or sympathetic extra-adrenal paragangliomas: insights from the largest single-institutional experience","volume":"118","author":"Ayala-Ramirez","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2024.114276_bib44","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3389\/fendo.2020.00061","article-title":"Temozolomide is a potential therapeutic tool for patients with metastatic pheochromocytoma\/paraganglioma-case report and review of the literature","volume":"11","author":"Tong","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.ejca.2024.114276_bib45","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1093\/ejendo\/lvad146","article-title":"Responses to systemic therapy in metastatic pheochromocytoma\/paraganglioma: a retrospective multicenter cohort study","volume":"189","author":"Fischer","year":"2023","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ejca.2024.114276_bib46","doi-asserted-by":"crossref","first-page":"285","DOI":"10.2217\/ije-2016-0015","article-title":"Durable response to lenvatinib in progressive, therapy-refractory, metastatic paraganglioma","volume":"3","author":"Jasim","year":"2016","journal-title":"Int J Endocr Oncol"},{"key":"10.1016\/j.ejca.2024.114276_bib47","doi-asserted-by":"crossref","first-page":"4162","DOI":"10.1200\/JCO.2008.21.3496","article-title":"Phase II study of high-dose [131I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma","volume":"27","author":"Gonias","year":"2009","journal-title":"J Clin Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924009328?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924009328?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T16:47:27Z","timestamp":1729615647000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804924009328"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":47,"alternative-id":["S0959804924009328"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2024.114276","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sunitinib for the treatment of patients with advanced pheochromocytomas or paragangliomas: The phase 2 non-randomized SUTNET clinical trial","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2024.114276","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"114276"}}